• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identifivatina and functional analysis of urate binding proteins

Research Project

Project/Area Number 21H02641
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionKanazawa University

Principal Investigator

Tamai Ikumi  金沢大学, 薬学系, 教授 (20155237)

Co-Investigator(Kenkyū-buntansha) 荒川 大  金沢大学, 薬学系, 准教授 (40709028)
若山 友彦  熊本大学, 大学院生命科学研究部(医), 教授 (70305100)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2023: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2022: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2021: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
Keywords尿酸 / 血清尿酸値 / CD38 / 炎症 / 免疫反応 / トランスポーター / 尿酸結合タンパク質 / 痛風 / 高尿酸血症 / NAD+ / 尿酸結晶 / NDFIP1 / URAT1 / ドチヌラド / 受容体 / センサー / 脂質代謝 / 臓器間相互作用 / 薬物動態
Outline of Research at the Start

尿酸の様々な組織・臓器・細胞への作用や血清尿酸値レベルは、生体の多様な因子によって調節されていると考えられる。しかし、関連因子情報は断片的であり、尿酸が何故ヒトにおいてのみ高いかなど基本的なことも含めて不明なのが現状である。本研究では、体内の尿酸を感知し、その情報を尿酸値調節や生体反応と結び付ける分子があると考え、それを尿酸センサーと名付け、その分子実体の同定を試みる。特に、高尿酸血症は高血圧や腎疾患あるいはNAFLDなど脂質関連疾患など多様な疾患との関連が示されており、本成果は高尿酸血症に伴う疾患発症機構解明へとつながるため、高尿酸血症と関連疾患の治療にも展開できると期待できる。

Outline of Final Research Achievements

To clarify why humans maintain high serum uric acid (SUA) levels and why SUA fluctuations are associated with pathological and physiological functions, this study hypothesized the completely new concept that there are urate-binding proteins in humans and they mediate urate associated physiological function and pathology. As a result, several urate-binding proteins were found and CD38, which was found as one of urate binding proteins, was further analyzed. It was found that crystallized uric acid increases CD38 expression in inflammatory cells, and that soluble uric acid inhibits NAD+-degrading enzyme activity of CD38. The maintenance of SUA has significance in modulating the activity of CD38. This is the first study which identified the presence of urate binding proteins and should be useful for further understanding of the roles of urate and the mechanisms for urate associated diseases in future.

Academic Significance and Societal Importance of the Research Achievements

ヒトと高等霊長類でのみ特異的に高い血清尿酸値SUAの意義とSUA変動と相関する多様な病態との関連性を明確にすべく、尿酸結合タンパク質が尿酸センサーとして働いていると仮定し、複数の尿酸結合タンパク質を見出した。その一つCD38については、結晶化尿酸と可溶性尿酸がCD38のNAD+分解酵素活性を調各々正負に相異なる方向に調節することをin vitroならびにCD38欠損マウス等のin vivo試験により示した。本成果は初めて尿酸が直接作用する生体タンパク質を同定するとともに、見出したNAD+は炎症・免疫・寿命など基本的な生理機能に関連しており、今後の尿酸研究に全く新しい情報となる。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Annual Research Report
  • 2021 Annual Research Report
  • Research Products

    (17 results)

All 2024 2023 2022 2021

All Journal Article (5 results) (of which Peer Reviewed: 4 results,  Open Access: 2 results) Presentation (12 results) (of which Int'l Joint Research: 3 results,  Invited: 3 results)

  • [Journal Article] Functional identification of soluble uric acid as an endogenous inhibitor of CD382024

    • Author(s)
      Wen S, Arakawa H, Yokoyama S, Shirasaka Y, Higashida H, Tamai I.
    • Journal Title

      eLife

      Volume: none Pages: 1-1

    • DOI

      10.7554/elife.96962.1

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Uric acid in health and disease. From physiological functions to pathological mechanisms.2024

    • Author(s)
      Wen S, Arakawa H, Tamai I.
    • Journal Title

      Pharmacology and Therapeutics

      Volume: 256 Pages: 108615-108615

    • DOI

      10.1016/j.pharmthera.2024.108615

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Unique binding sites of uricosuric agent dotinurad for selective inhibition of renal uric acid reabsorptive transporter URAT12024

    • Author(s)
      Fujita K, Isozumi N, Zhu Q, Matsubayashi M, Taniguchi T, Arakawa H, Shirasaka Y, Mori E, Tamai I.
    • Journal Title

      Journal of Pharmacology and Experimental Therapeutics.

      Volume: 390 Issue: 1 Pages: 1-9

    • DOI

      10.1124/jpet.124.002096

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] CD38 activation by monosodium urate crystals contributes to inflammatory responses in human and murine macrophages2021

    • Author(s)
      Wen S, Arakawa H, Tamai I
    • Journal Title

      Biochemical and Biophysical Research Communications

      Volume: 581 Pages: 6-11

    • DOI

      10.1016/j.bbrc.2021.10.010

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] 尿酸再吸収トランスポーターURAT1&GLUT92021

    • Author(s)
      玉井郁巳
    • Journal Title

      ファルマシア 57:897-901, 2021.

      Volume: 57 Pages: 897-901

    • NAID

      130008095686

    • Related Report
      2021 Annual Research Report
  • [Presentation] 輸送体を基盤とした薬物・生理的物質の 動態と作用に関する研究2024

    • Author(s)
      玉井郁巳
    • Organizer
      日本薬学会第144年会
    • Related Report
      2023 Annual Research Report
    • Invited
  • [Presentation] Specific binding of uric acid to NDFIP1 associates with hyperuricemia-induced ferroptosis2024

    • Author(s)
      Zhu Q, Arakawa H, Shirasaka Y, Tamai I
    • Organizer
      日本薬学会第144年会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Specific binding of uric acid to NDFIP1 associates with hyperuricemia-induced ferroptosis2023

    • Author(s)
      Zhu Q, Arakawa H, Isozumi N, Shirasaka Y, Mori E, Tamai I
    • Organizer
      2023 American College of Rheumatology Covergence
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Soluble uric acid is an endogenous inhibitor of CD382023

    • Author(s)
      Wen S, Arakawa H, Ypkoyama S, Shirasaka Y, Higashida H, Tamai I
    • Organizer
      2023 American College of Rheumatology Covergence
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] トランスポーター研究の進歩と展望2023

    • Author(s)
      玉井郁巳
    • Organizer
      第30回HAB研究機構学術年会
    • Related Report
      2023 Annual Research Report
    • Invited
  • [Presentation] Potentiation of Uricosuric Effect of Dotinurad by Trans-Inhibition of Uric Acid Reabsorptive Transporter URAT12023

    • Author(s)
      Fujita K, Zhu Q, Arakawa H, Shirasaka Y, Tamai I
    • Organizer
      第38回日本薬物動態学会年会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Molecular identification of specific binding site of dotinurad to uric acid transporter URAT1 responsible for its selective uric acid reuptake inhibition2023

    • Author(s)
      Fujita K, Isozumi N, Zhu Q, Matsubayashi M, Taniguchi T, Arakawa H, Shirasaka Y, Mori E, Tamai I
    • Organizer
      第38回日本薬物動態学会年会
    • Related Report
      2023 Annual Research Report
  • [Presentation] CD38 mediates the distinct roles of soluble uric acid and MSU crystals in gouty inflammation2023

    • Author(s)
      Shijie Wen, Hiroshi Arakawa, Kazuki Himi, Yoshiyuki Shirasaka, Ikumi Tamai
    • Organizer
      第56回日本痛風・尿酸核酸学会総会
    • Related Report
      2022 Annual Research Report
  • [Presentation] Trans-inhibitory effect of dotinurad, a uricosuric agent on uric acid reabsorptive transporter URAT12022

    • Author(s)
      藤田一輝、朱秋楠、荒川大、玉井郁巳
    • Organizer
      第96回日本薬理学会年会
    • Related Report
      2022 Annual Research Report
  • [Presentation] Specific binding of uric acid to NDFIP1 associates with hyperuricemia-induced liver fat accumulation2022

    • Author(s)
      Qiunan ZHU, Hiroshi ARAKAWA, Aimi TANIGUCHI, Yurika NAGAO, Yoshiyuki SHIRASAKA, Ikumi TAMAI
    • Organizer
      第96回日本薬理学会年会
    • Related Report
      2022 Annual Research Report
  • [Presentation] CD38 activation contributes to gouty inflammation in vitro2022

    • Author(s)
      Wen S, Arakawa S, Tamai I.
    • Organizer
      日本痛風・尿酸核酸学会総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Transporter-mediated Regulation and Drug Interaction of Serum Uric Acid2021

    • Author(s)
      Ikumi Tamai
    • Organizer
      Forbidden City International Pharmacist Conference 2021 China
    • Related Report
      2021 Annual Research Report
    • Int'l Joint Research / Invited

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi